miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling
Rita El Helou,
Guillaume Pinna,
Olivier Cabaud,
Julien Wicinski,
Ricky Bhajun,
Laurent Guyon,
Claire Rioualen,
Pascal Finetti,
Abigaelle Gros,
Bernard Mari,
Pascal Barbry,
Francois Bertucci,
Ghislain Bidaut,
Annick Harel-Bellan,
Daniel Birnbaum,
Emmanuelle Charafe-Jauffret,
Christophe Ginestier
Affiliations
Rita El Helou
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Guillaume Pinna
Plateforme ARN interférence (PARi), Service de Biologie Intégrative et de Génétique Moléculaire, I2BC, UMR 9198, CEA Saclay, 91191 Gif-sur-Yvette, France; Université Paris-Sud, Gif-sur-Yvette, 91400 Orsay, France
Olivier Cabaud
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Julien Wicinski
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Ricky Bhajun
Université Grenoble-Alpes, 38000 Grenoble, France; CEA, iRTSV, Biologie à Grande Echelle, 38054 Grenoble, France; INSERM, U1038, 38054 Grenoble, France
Laurent Guyon
Université Grenoble-Alpes, 38000 Grenoble, France; CEA, iRTSV, Biologie à Grande Echelle, 38054 Grenoble, France; INSERM, U1038, 38054 Grenoble, France
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Abigaelle Gros
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Bernard Mari
CNRS, Institute of Molecular and Cellular Pharmacology, Sophia Antipolis, 06560 Valbonne, France; University of Nice Sophia Antipolis, 06000 Nice, France
Pascal Barbry
CNRS, Institute of Molecular and Cellular Pharmacology, Sophia Antipolis, 06560 Valbonne, France; University of Nice Sophia Antipolis, 06000 Nice, France
Francois Bertucci
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Plateforme ARN interférence (PARi), Service de Biologie Intégrative et de Génétique Moléculaire, I2BC, UMR 9198, CEA Saclay, 91191 Gif-sur-Yvette, France; Université Paris-Sud, Gif-sur-Yvette, 91400 Orsay, France
Daniel Birnbaum
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Emmanuelle Charafe-Jauffret
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France
Christophe Ginestier
Molecular Oncology “Equipe labellisée Ligue Contre le Cancer,” Aix-Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille, France; Corresponding author
Summary: Breast cancer stem cells (bCSCs) have been implicated in tumor progression and therapeutic resistance; however, the molecular mechanisms that define this state are unclear. We have performed two microRNA (miRNA) gain- and loss-of-function screens to identify miRNAs that regulate the choice between bCSC self-renewal and differentiation. We find that micro-RNA (miR)-600 silencing results in bCSC expansion, while its overexpression reduces bCSC self-renewal, leading to decreased in vivo tumorigenicity. miR-600 targets stearoyl desaturase 1 (SCD1), an enzyme required to produce active, lipid-modified WNT proteins. In the absence of miR-600, WNT signaling is active and promotes self-renewal, whereas overexpression of miR-600 inhibits the production of active WNT and promotes bCSC differentiation. In a series of 120 breast tumors, we found that a low level of miR-600 is correlated with active WNT signaling and a poor prognosis. These findings highlight a miR-600-centered signaling network that governs bCSC-fate decisions and influences tumor progression. : El Helou et al. identify miRNAs that are able to balance bCSC fate. They find that miR-600 silencing results in bCSC expansion, while its overexpression reduces bCSC self-renewal. miR-600 was further found to regulate WNT signaling through SCD1, and miR-600 expression correlates with clinical outcome.